Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Enterprise Value (2016 - 2025)

International Stem Cell (ISCO) has disclosed Enterprise Value for 16 consecutive years, with -$966000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 26.09% to -$966000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$966000.0, a 26.09% increase, with the full-year FY2024 number at -$1.2 million, up 22.54% from a year prior.
  • Enterprise Value was -$966000.0 for Q3 2025 at International Stem Cell, down from -$920000.0 in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$171000.0 in Q4 2021 to a low of -$1.6 million in Q4 2023.
  • A 5-year average of -$991000.0 and a median of -$966000.0 in 2025 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 75.18% in 2021, then tumbled 333.92% in 2022.
  • International Stem Cell's Enterprise Value stood at -$171000.0 in 2021, then crashed by 333.92% to -$742000.0 in 2022, then tumbled by 114.02% to -$1.6 million in 2023, then grew by 22.54% to -$1.2 million in 2024, then grew by 21.46% to -$966000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Enterprise Value are -$966000.0 (Q3 2025), -$920000.0 (Q2 2025), and -$1.5 million (Q1 2025).